Overview

A First Time in Human (FTIH) Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Single and Repeat Doses of GSK3884464 in Healthy Participants

Status:
Recruiting
Trial end date:
2022-10-18
Target enrollment:
Participant gender:
Summary
This will be a FTIH study which aims to evaluate safety, tolerability, pharmacokinetics (PK) and pharmacodynamics (PD) of single and repeat oral doses of GSK3884464 administered to healthy participants.
Phase:
Phase 1
Details
Lead Sponsor:
GlaxoSmithKline